Views & Analysis Dreaming big with small molecules Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade.
News Clovis hopes to get ahead of rivals in prostate cancer with ... Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an
News Tesaro stock rockets as rumours of Roche takeover abound Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.
Oncology Clovis' Rubraca close to EU approval in ovarian cancer CHMP backs conditional approval for PARP drug
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.